Editas Medicine, Inc. vs UnitedHealth Group Incorporated — Stock Comparison

Editas Medicine, Inc. (EDIT) and UnitedHealth Group Incorporated (UNH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.

Q·Score Winner
UnitedHealth Group Incorporated
UNH7.1/10vs 5.6/10

UnitedHealth Group Incorporated clearly outscores Editas Medicine, Inc. on Q·Score (7.1 vs 5.6 out of 10), led by Quality (6.2 vs 0.2) and Sentiment (8.3 vs 5.4). Editas Medicine, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for EDIT (+128.1%) than for UNH (+28.1%).

Price Performance

Normalised to 100 at period start — shows relative performance.

Loading…
EDITUNH

Q·Score Breakdown

5.6
Neutral
Overall
7.1
Bullish
0.2
Quality
6.2
9.2
Health
5.8
7.8
Growth
7.5
6.9
Valuation
8.1
5.4
Sentiment
8.3
EDIT

Clean balance sheet with low leverage (0.1× debt-to-equity).

currently unprofitable (-157% margin).

UNH

85% of 26 covering analysts have a positive rating.

Analyst Consensus

Neutral
+128.1%
Target $6.00
9 analysts
Bullish
+28.1%
Target $481.72
25 analysts

Fundamentals

EDIT
UNH
Trailing P/E
24.1×
-3.5×
Forward P/E
16.7×
-157.32%
Profit Margin
3.14%
-80.75%
Gross Margin
19.72%
-118.82%
ROE
14.15%
232.30%
Revenue Growth
0.40%
Earnings Growth
61.50%
2.09
Beta
0.62
Dividend Yield
2.42%
$404M
Market Cap
$337.4B
52-Week Range
EDIT
$234% of range$5
UNH
$25658% of range$462

Frequently Asked Questions

EDIT vs UNH: which stock scores better overall?

Based on Q·Score, UnitedHealth Group Incorporated (UNH) scores 7.1/10 versus Editas Medicine, Inc. (EDIT) at 5.6/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.

Which has better revenue growth: EDIT or UNH?

Editas Medicine, Inc. (EDIT) scores higher on Growth (7.8/10 vs 7.5/10). Editas Medicine, Inc. reports revenue growth (232.3% YoY) while UnitedHealth Group Incorporated reports (0.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.

Is EDIT or UNH more attractively valued?

UnitedHealth Group Incorporated (UNH) scores higher on Valuation (8.1/10 vs 6.9/10). Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.

What do analysts say about EDIT vs UNH?

There are 9 analysts covering EDIT with a consensus price target of $6.00, and 25 analysts covering UNH with a consensus target of $481.72. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.

Which is more profitable: EDIT or UNH?

UnitedHealth Group Incorporated (UNH) scores higher on Quality (6.2/10 vs 0.2/10). Net profit margin: EDIT at -157.3%, UNH at 3.1%. Quality scores reflect profit margins, return on equity, and free cash flow generation.

Which has stronger financial health: EDIT or UNH?

Editas Medicine, Inc. (EDIT) scores higher on Financial Health (9.2/10 vs 5.8/10). Market beta: EDIT at 2.09, UNH at 0.62. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.

What are the market caps of EDIT and UNH?

Editas Medicine, Inc. (EDIT) has a market capitalisation of $404M, while UnitedHealth Group Incorporated (UNH) has a market cap of $337.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.

Do EDIT or UNH pay dividends?

EDIT does not currently pay a dividend, while UNH pays a dividend yield of 2.42%. Dividend yields fluctuate with share price and company payout decisions.

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →

Data provided by Yahoo Finance ·  Updated on each page load ·  For informational purposes only · Not financial advice · Quantify.biz © 2026